Defunct Company
Total Trials
21
As Lead Sponsor
As Collaborator
0
Total Enrollment
2,696
NCT00428766
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 30, 2005
Completion: Dec 31, 2007
NCT00318370
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Phase: Phase 2
Start: May 31, 2006
Completion: Jun 30, 2010
NCT00325494
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Completion: Sep 30, 2008
NCT00570713
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
Start: Dec 31, 2007
Completion: Dec 31, 2009
NCT00738699
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
Start: Sep 30, 2008
Completion: Jan 31, 2012
NCT00738582
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Start: Dec 31, 2008
Completion: Jan 10, 2014
NCT00847054
A Study of of MORAb-004 in Subjects With Solid Tumors
Start: Mar 31, 2009
Completion: Apr 30, 2014
NCT00849667
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Phase: Phase 3
Start: Apr 16, 2009
Completion: Apr 12, 2013
NCT01004380
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
Start: Nov 30, 2009
Completion: Oct 31, 2012
NCT01018563
An Open Label Extension Study of the Efficacy of MORAb-003
Start: Jan 13, 2010
Completion: Mar 5, 2013
NCT01123304
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
Start: May 31, 2010
Completion: Mar 31, 2012
NCT01212276
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
Start: Dec 31, 2010
Completion: Sep 30, 2012
NCT01203618
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Start: Feb 28, 2011
Completion: Aug 31, 2013
NCT01218516
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Start: Jun 27, 2011
Completion: Nov 1, 2013
NCT01521325
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Start: Sep 30, 2011
Completion: Mar 31, 2013
NCT01507545
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Start: Mar 27, 2012
Completion: Oct 20, 2013
NCT01574716
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
Start: Aug 7, 2012
Completion: Aug 2, 2016
NCT01357759
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
Start: May 31, 2013
Completion: Jul 31, 2014
NCT01761240
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Start: Jun 19, 2013
Completion: Feb 9, 2016
NCT01748721
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Start: Nov 30, 2013
Completion: May 31, 2015
NCT02357147
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
Start: Nov 3, 2015
Completion: Nov 30, 2018